Last reviewed · How we verify
Integral ticagrelor
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events. Used for Acute coronary syndrome (ACS), Secondary prevention of thrombotic cardiovascular events.
At a glance
| Generic name | Integral ticagrelor |
|---|---|
| Also known as | Brilique |
| Sponsor | Collegium Medicum w Bydgoszczy |
| Drug class | P2Y12 platelet receptor antagonist |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, blocking platelet activation and aggregation. This antiplatelet effect reduces the formation of blood clots and is used to prevent cardiovascular events in acute coronary syndromes and other thrombotic conditions. The 'integral' formulation likely refers to an extended-release or optimized formulation of the standard ticagrelor molecule.
Approved indications
- Acute coronary syndrome (ACS)
- Secondary prevention of thrombotic cardiovascular events
Common side effects
- Bradycardia
- Dyspnea
- Bleeding
- Ventricular pauses
Key clinical trials
- Chewed Versus Integral Pill of Ticagrelor (PHASE4)
- Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome (PHASE4)
- Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study (PHASE4)
- Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? ) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |